BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Kim ES, Kang B. Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn’s disease. World J Gastroenterol 2023; 29(18): 2784-2797 [PMID: 37274072 DOI: 10.3748/wjg.v29.i18.2784]
URL: https://www.wjgnet.com/1007-9327/full/v29/i18/2784.htm
Number Citing Articles
Jeffrey Shen, Megumi Sugita, Andrea Linares-Lopez, Suma Shah, Christopher Eckstein, Elijah Lackey. Adalimumab as treatment for neurosarcoidosis: A case seriesJournal of the Neurological Sciences 2024; 460: 123018 doi: 10.1016/j.jns.2024.123018
Chao-Tao Tang, Fang Yin, Yitian Yin, Zide Liu, Shunhua Long, Chun-Yan Zeng, Yong Chen, You-Xiang Chen. Are Radiomic Spleen Features Useful for Assessing the Response to Infliximab in Patients With Crohn's Disease? A Multicenter StudyClinical and Translational Gastroenterology 2024; 15(5): e00693 doi: 10.14309/ctg.0000000000000693